THMO ThermoGenesis Dashboard

ThermoGenesis Holdings, Inc. engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It operates through the Device and Clinical Development segment. The Device segment includes the development and commercialization of automated technologies for cell-based therapeutics and bioprocessing. The Clinical Development segment utilizes autologous stem cell-based therpeutics. The company was founded by Philip H. Coelho in 1986 and is headquartered in Rancho Cordova, CA.

Company profile

Ticker

THMO

Exchange

NASDAQ

Website

thermogenesis.com

CEO

Xiaochun Xu

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Other Industrial Machinery Manufacturing

Industry (SIC)

Laboratory Apparatus & Furniture

Kewaunee Scientific • Misonix • Reflect Scientific ...

Former names

CESCA THERAPEUTICS INC., THERM0GENESIS CORP, THERMOGENESIS CORP

SEC CIK

0000811212

Corporate docs

Articles of Incorporation & Bylaws

IRS number

943018487

THMO stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Apr 21

The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq

18 Mar 21

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 17)

The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes

17 Mar 21

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 16)

Earnings Scheduled For March 17, 2021

17 Mar 21

Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations

14 Mar 21

Press releases

Pro users get this 30m faster

ThermoGenesis Holdings Announces 2020 Year End Financial Results and Provides Corporate Update

17 Mar 21

RANCHO CORDOVA, Calif., March 17, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported

ThermoGenesis Holdings, Inc. to Host Earnings Call

17 Mar 21

NEW YORK, NY / ACCESSWIRE / March 17, 2021 / ThermoGenesis Holdings, Inc. (NASDAQ:THMO) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 17, 2021 at 4:30 PM Eastern

ThermoGenesis Holdings to Announce Financial Results for the Fourth Quarter Ended December 31, 2020 and Provide a Corporate Strategic Update

10 Mar 21

RANCHO CORDOVA, Calif., March 10, 2021 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (NASDAQ:THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field,

ThermoGenesis Holdings Begins a Year of Celebration of its 35th Anniversary in the Cell Banking and Cell Therapy Industry

17 Feb 21

ThermoGenesis Holdings Launches a GMP Compliant Automated Cell Washing and Reformulation System -- PXP™-LAVARE -- for CAR-T Manufacturing

3 Feb 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

17 Mar 21

13 Apr 21

31 Dec 21

Financial summary

Financial statements Chart THMO financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Jun 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	7.16M	7.16M	7.16M	7.16M	7.16M	7.16M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	472K	741.33K	844.67K	1.2M
Cash used (since last report)	n/a	n/a	1.62M	2.55M	2.91M	4.13M
Cash remaining	n/a	n/a	5.54M	4.61M	4.25M	3.03M
Runway (months of cash)	n/a	n/a	11.7	6.2	5.0	2.5

Beta Read what these cash burn values mean

Recent insider trades

THMO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
4 Jun 20	Donaghy Debra	Stock Option Common Stock	Grant	Aquire A	No	No	5.94	10,000	59.4K	10,000
4 Jun 20	Westgate Mark	Stock Option Common Stock	Grant	Aquire A	No	No	5.94	10,000	59.4K	10,000
4 Jun 20	Joseph Thomis	Stock Option Common Stock	Grant	Aquire A	No	No	5.94	10,000	59.4K	10,000
4 Jun 20	Medford Russell M	Stock Option Common Stock	Grant	Aquire A	No	No	5.94	10,000	59.4K	10,000
4 Jun 20	Cauble Jeffery	Stock Option Common Stock	Grant	Aquire A	No	No	5.94	40,000	237.6K	40,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

THMO institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders	Current	Prev Q	Change
Total holders	0	15	EXIT
Opened positions	0	4	EXIT
Closed positions	15	6	+150.0%
Increased positions	0	2	EXIT
Reduced positions	0	2	EXIT

13F shares	Current	Prev Q	Change
Total value	0	2.3M	EXIT
Total shares	0	243.93K	EXIT
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Renaissance Technologies	0	$0

Largest transactions	Shares	Bought/sold	Change
BLK Blackrock	0	-94.27K	EXIT
Vanguard	0	-56.17K	EXIT
Diametric Capital	0	-38.26K	EXIT
Prelude Capital Management	0	-25.79K	EXIT
Geode Capital Management	0	-22.41K	EXIT
BAC Bank Of America	0	-3.2K	EXIT
MS Morgan Stanley	0	-2.59K	EXIT
Freestone Capital	0	-550	EXIT
WFC Wells Fargo & Co.	0	-282	EXIT
AdvisorNet Financial	0	-206	EXIT

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Baxter International • Vericel • BioCardia • Plus Therapeutics • Zimmer Biomet • Pluristem Therapeutics • Mesoblast • Celyad Oncology

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accuracy, Aid, Alex, analyzed, Azar, BioHit, brand, cap, collateral, Comerica, Commissioner, contest, contradictory, counterparty, debit, diagnosing, disposition, EUA, FDC, Governor, Gurugram, Hefei, Hefer, HHS, IRC, lieu, mathematical, methodology, mortgage, Newsom, NOL, obsolete, outweigh, Paycheck, PPP, preceding, rank, RDO, SBA, Secretary, spending, staffing, supernatant, switch, threat, unapproved, unconsolidated, understated, voluntarily, wait, winding

Removed: accelerate, accepting, addressed, alleged, arrangement, assist, bodily, borne, building, cancer, cardiology, cardiovascular, CEO, Cesca, CFO, challenge, Chinese, chronic, codified, CODM, complaint, concentrate, constituted, Council, coupled, cumulative, dealing, deferral, dermal, discretionary, disposal, documented, dramatically, ease, employed, enterprise, ERP, expanded, expanding, exposure, final, flow, freely, freezing, function, fundamental, GCP, geared, GLP, Golden, harvest, headcount, IEC, implementation, improved, informed, initiation, involuntary, IRB, jointly, largely, leader, leadership, leaving, leverage, Meditech, million, Ministry, novacord, orthopedic, output, participant, partnership, phase, population, practical, practice, preferred, presenting, proven, recovery, reducing, reduction, regularly, reimburse, remained, sample, solution, successive, target, tissue, Totipotent, transplantation, treat, utilizing, vascular, vested, viability, viable

From filing 10-K 2020 FY